Coral Labs.

how big is Coral Labs.?

As of Jun 06, Coral Laboratories Ltd has a market capitalization of 219.18 Cr and reported net sales of 115.01 Cr and a net profit of 24.15 Cr over the latest four quarters. Shareholder's funds are valued at 177.50 Cr, with total assets of 205.68 Cr as of Mar'24.

Market Cap: As of Jun 06, Coral Laboratories Ltd has a market capitalization of 219.18 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, the company reported Net Sales of 115.01 Cr and a Net Profit of 24.15 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 177.50 Cr, and the Total Assets amount to 205.68 Cr.

What does Coral Labs. do?

Coral Laboratories Ltd is a micro-cap pharmaceutical company established in 1997, focusing on Generic Branded, Nutraceuticals, OTC, and Herbal Medicines. As of March 2025, it reported net sales of 28 Cr and a net profit of 3 Cr, with a market cap of Rs 216 Cr.

Overview: <BR>Coral Laboratories Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of Generic Branded, Nutraceuticals, OTC, and Herbal Medicines.<BR><BR>History: <BR>Coral Laboratories Ltd was established in February 1997. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 28 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 3 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 216 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.33% <BR>Debt Equity: -0.49 <BR>Return on Equity: 13.93% <BR>Price to Book: 1.22 <BR><BR>Contact Details: <BR>Address: SF-206 Silver Oak Complex, BPC Road Vadodara Gujarat : 390020 <BR>Tel: 91-022-2500 5245/46 <BR>Email: cs@corallab.com <BR>Website: http://www.corallab.com

Who are in the management team of Coral Labs.?

As of March 2023, the management team of Coral Labs includes Sheela R Kamdar (Independent Director), Girish Dhameja (Whole-time Director), Sushma Shashi Kadkade (Director & CFO), Saurabh Shah (Independent Director), Ruchi Anjaria (Company Secretary & Compliance Officer), Malay Doshi (Independent Director), and Rajendrasinh Rana (Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Coral Labs includes the following individuals:<BR><BR>1. Sheela R Kamdar - Independent Director<BR>2. Girish Dhameja - Whole-time Director<BR>3. Sushma Shashi Kadkade - Director & CFO<BR>4. Saurabh Shah - Independent Director<BR>5. Ruchi Anjaria - Company Secretary & Compliance Officer<BR>6. Malay Doshi - Independent Director<BR>7. Rajendrasinh Rana - Director<BR><BR>Each member plays a distinct role within the organization, contributing to its governance and operational management.

Has Coral Labs. declared dividend?

Coral Laboratories Ltd has declared a 20% dividend, amounting to 2 per share, with an ex-date of September 20, 2024. The company has shown varying total returns, with significant gains over the long term despite recent price fluctuations.

Coral Laboratories Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 20 Sep 24<BR><BR>Dividend Yield: 0.33%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -24.78%, with a dividend return of 0%, resulting in a total return of -24.78%.<BR><BR>Over the past year, the price return was 18.66%, the dividend return was 0.35%, leading to a total return of 19.01%.<BR><BR>In the 2-year period, the price return was 157.18%, the dividend return was 0.84%, culminating in a total return of 158.02%.<BR><BR>For the 3-year period, the price return was 137.76%, the dividend return was 0.83%, resulting in a total return of 138.59%.<BR><BR>In the last 4 years, the price return was 31.4%, with a dividend return of 0.37%, leading to a total return of 31.77%.<BR><BR>Over the 5-year period, the price return was 214.6%, the dividend return was 1.00%, resulting in a total return of 215.6%.<BR><BR>Overall, Coral Laboratories Ltd has recently declared a dividend while showing varying total returns over different periods, with significant gains over the longer term despite some recent fluctuations in price returns.

Who are the peers of the Coral Labs.?

Coral Labs.' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Coral Labs. has below average growth and management risk, with a 1-year return of 22.37%.

Peers: The peers of Coral Labs. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Kimia Bioscien., Pharmaids Pharma, Alpa Laboratorie, and Syschem (India).<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk, including Coral Labs., Natural Capsules, Kimia Bioscien., Pharmaids Pharma. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while below average growth is noted at Divi's Lab., Torrent Pharma, Kimia Bioscien., Pharmaids Pharma, and the rest. Excellent capital structure is found at Sun Pharma.Inds., Cipla, Dr Reddy's Labs., and Alpa Laboratorie, while Coral Labs., Torrent Pharma, and Natural Capsules have good capital structure, and the rest have below average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Kimia Bioscien. has the lowest at -4.25%. Coral Labs.'s 1-year return of 22.37% is significantly higher than Kimia Bioscien. but lower than Divi's Lab. Additionally, Natural Capsules, Kimia Bioscien., Pharmaids Pharma, and Alpa Laboratorie have negative six-month returns.

What is the technical trend for Coral Labs.?

As of June 2, 2025, Coral Labs is in a bearish trend, supported by negative indicators across multiple time frames, including bearish MACD, RSI, Bollinger Bands, and moving averages.

As of 2 June 2025, the technical trend for Coral Labs has changed from mildly bearish to bearish. The weekly MACD is bearish, and the monthly MACD is mildly bearish, indicating a negative momentum shift. The RSI on a monthly basis is bearish, further supporting the bearish stance. Both the weekly and monthly Bollinger Bands are bearish, suggesting price volatility is trending downwards. Daily moving averages are also bearish, reinforcing the negative outlook. The KST is bearish on a weekly basis and mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on both time frames. Overall, the current technical stance is bearish with a strong emphasis on negative indicators across multiple time frames.

Who are the top shareholders of the Coral Labs.?

The top shareholder of Coral Labs is Chetan Navinchandra Doshi, holding 51.54%. The highest public shareholder is Meeta Samir Sheth at 1.84%, with individual investors collectively owning 20.91% of the shares.

The top shareholders of Coral Labs are primarily the promoters, with Chetan Navinchandra Doshi holding the largest share at 51.54%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares. The highest public shareholder is Meeta Samir Sheth, who holds 1.84%. Additionally, individual investors collectively hold 20.91% of the shares.

How has been the historical performance of Coral Labs.?

Coral Labs has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales rising from 78.12 Cr to 115.01 Cr and profit after tax increasing from 6.45 Cr to 24.16 Cr. However, cash flow from operating activities declined from 12.00 Cr to -1.00 Cr during the same period.

Answer:<BR>The historical performance of Coral Labs shows a significant upward trend in net sales and profitability over the past few years.<BR><BR>Breakdown:<BR>Coral Labs has demonstrated a strong growth trajectory in net sales, increasing from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. This growth is reflected in the total operating income, which also rose from 78.12 Cr in March 2023 to 115.01 Cr in March 2025. The company's operating profit (PBDIT) excluding other income surged from 3.81 Cr in March 2023 to 26.24 Cr in March 2025, indicating improved operational efficiency. Profit before tax followed a similar trend, climbing from 8.23 Cr in March 2023 to 32.47 Cr in March 2025, while profit after tax increased from 6.45 Cr to 24.16 Cr in the same period. The earnings per share (EPS) also saw a substantial rise from 18.07 in March 2023 to 67.68 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from 174.35 Cr in March 2023 to 229.46 Cr in March 2025, with total liabilities increasing from 174.35 Cr to 229.46 Cr, indicating a proportional growth in the company's financial structure. Cash flow from operating activities, however, showed a negative trend, moving from a positive 12.00 Cr in March 2023 to a negative 1.00 Cr in March 2025, suggesting challenges in cash generation despite strong profit growth. Overall, Coral Labs has improved its financial performance significantly over the years, particularly in sales and profitability metrics.

Is Coral Labs. overvalued or undervalued?

As of November 17, 2025, Coral Labs is considered undervalued with a PE ratio of 10.25 and an EV to EBIT of 5.62, significantly lower than its expensive industry peers, suggesting potential for recovery despite a challenging year with a -40.17% stock return.

As of 17 November 2025, Coral Labs has moved from a very attractive to an attractive valuation grade. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 10.25, an EV to EBIT of 5.62, and a Price to Book Value of 0.85, which all suggest a favorable valuation relative to its peers.<BR><BR>In comparison to its industry peers, Coral Labs stands out with a significantly lower PE ratio than Sun Pharma (36.69) and Divi's Lab (69.78), both classified as expensive. Additionally, Coral Labs' EV to EBITDA of 4.95 is also more attractive than the industry average, reinforcing its undervalued status. Despite a challenging year with a stock return of -40.17%, the company's valuation metrics indicate potential for recovery and growth compared to the Sensex.

When is the next results date for Coral Laboratories Ltd?

The next results date for Coral Laboratories Ltd is 13 February 2026.

The next results date for Coral Laboratories Ltd is scheduled for 13 February 2026.

Are Coral Laboratories Ltd latest results good or bad?

Coral Laboratories Ltd's latest results are concerning, showing a 54.70% year-on-year decline in net profit and a 6.22% drop in net sales, indicating significant operational challenges and reliance on non-operating income. Overall, the financial metrics suggest a negative outlook for the company.

Coral Laboratories Ltd's latest results are concerning and indicate a significant decline in performance. For the third quarter of FY26, the company reported a net profit of ₹2.78 crores, which represents a staggering 54.70% decrease year-on-year. Additionally, net sales fell by 6.22% to ₹21.56 crores, continuing a troubling trend of declining revenues throughout the fiscal year.<BR><BR>The operating margin, excluding other income, dropped to 8.77%, the lowest in seven quarters, down from 27.45% in the same quarter last year. This sharp decline in profitability reflects severe operational challenges and suggests that the company is struggling to maintain its core business profitability. Moreover, the profit after tax (PAT) margin also decreased significantly from 26.71% to 12.89%.<BR><BR>The reliance on non-operating income has raised red flags about the sustainability of earnings, with other income accounting for 67.30% of profit before tax. This dependency indicates that the core pharmaceutical operations are barely profitable, which is a critical concern for investors.<BR><BR>Overall, the results indicate a company in distress, with deteriorating financial metrics and significant challenges ahead. Investors should approach with caution, as the outlook appears negative without clear signs of recovery or stabilization in the near future.

Should I buy, sell or hold Coral Laboratories Ltd?

Why is Coral Laboratories Ltd falling/rising?

As of 02-May, Coral Laboratories Ltd's stock price is rising to 424.95, up 0.91%. This increase is driven by short-term gains and positive technical indicators, despite a significant long-term decline of -34.22% over the past year and ongoing negative financial results.

As of 02-May, Coral Laboratories Ltd's stock price is rising, currently at 424.95, with a change of 3.85 (0.91%) up. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.88% today and has shown a consecutive gain over the last three days, accumulating a total return of 3.33% during this period. Additionally, the current price is higher than the 5-day, 20-day, and 50-day moving averages, indicating a short-term bullish trend.<BR><BR>Despite these positive indicators, it is important to note that the stock has faced challenges in the longer term. Over the past year, it has generated a return of -34.22%, significantly underperforming the market, which has seen a return of 2.53%. The company has also reported negative results for the last four consecutive quarters, with a notable decline in net sales and profits. However, the stock's attractive valuation, being net-debt free and trading at a fair value compared to its peers, may be contributing to the recent rise in price as investors look for potential recovery signals.

Which are the latest news on Coral Labs.?